130 related articles for article (PubMed ID: 3477462)
1. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies.
Thyss A; Milano G; Deville A; Manassero J; Renee N; Schneider M
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):843-7. PubMed ID: 3477462
[TBL] [Abstract][Full Text] [Related]
2. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
4. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.
Vassal G; Valteau D; Bonnay M; Patte C; Aubier F; Lemerle J
Pediatr Hematol Oncol; 1990; 7(1):71-7. PubMed ID: 2397170
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
8. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate in acute lymphocytic leukemia.
Freeman AI; Wang JJ; Sinks LF
Cancer Treat Rep; 1977 Jul; 61(4):727-31. PubMed ID: 267510
[TBL] [Abstract][Full Text] [Related]
10. CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group.
Milano G; Thyss A; Serre Debeauvais F; Laureys G; Benoit Y; Deville A; Dutour C; Robert A; Otten J; Behar C
Eur J Cancer; 1990 Apr; 26(4):492-5. PubMed ID: 2141516
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
[TBL] [Abstract][Full Text] [Related]
12. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia.
Borsi JD; Sagen E; Romslo I; Slørdal L; Moe PJ
Cancer Chemother Pharmacol; 1990; 27(2):164-7. PubMed ID: 2249335
[TBL] [Abstract][Full Text] [Related]
13. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.
Seidel H; Andersen A; Kvaløy JT; Nygaard R; Moe PJ; Jacobsen G; Lindqvist B; Slørdal L
Leuk Res; 2000 Mar; 24(3):193-9. PubMed ID: 10739001
[TBL] [Abstract][Full Text] [Related]
14. Factors Affecting the Upper Limit of the Methotrexate (MTX) CSF Levels Achievable in Children With Brain Tumors Treated With High-dose Intravenous MTX.
Shkalim Zemer V; Toledano H; Ash S; Cohen E; Yaniv I; Cohen IJ
J Pediatr Hematol Oncol; 2016 Oct; 38(7):544-8. PubMed ID: 27403773
[TBL] [Abstract][Full Text] [Related]
15. [New aspects of the determination of blood methotrexate levels in leukemic children].
Schuler D; Borsi J; Koós R; Révész T; Kardos G; Somló P
Monatsschr Kinderheilkd; 1986 Oct; 134(10):765-8. PubMed ID: 3467178
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma.
Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ
Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions.
Parker RI; Forman EN; Krumm KF; Abeel MJ; Martin HF
Ther Drug Monit; 1986; 8(4):393-9. PubMed ID: 3469802
[TBL] [Abstract][Full Text] [Related]
18. Effect of probenecid on cerebrospinal fluid methotrexate kinetics.
Howell SB; Olshen RA; Rice JA
Clin Pharmacol Ther; 1979 Nov; 26(5):641-6. PubMed ID: 498706
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate-vindesine association in leukemia: pharmacokinetic study.
Tubiana N; Lena N; Barbet J; Imbert AM; Lejeune C; Maraninchi D; Sainty D; Sebahoun G; Gastaut JA; Cano JP
Med Oncol Tumor Pharmacother; 1985; 2(2):99-102. PubMed ID: 3864001
[TBL] [Abstract][Full Text] [Related]
20. Intermediate dose of methotrexate toxicity in non-Hodgkin lymphoma.
Uluoğlu C; Oğuz A; Timlioğlu O; Biberoğlu G; Hasanoğlu A
Gen Pharmacol; 1999 Feb; 32(2):215-8. PubMed ID: 10188622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
